Sat.Sep 02, 2023 - Fri.Sep 08, 2023

article thumbnail

New Product Planning: The Function's Evolution in Pharma

PharmExec

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.

article thumbnail

Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan

Fierce Pharma

Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.

Marketing 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HHS Issues Proposal Bolstering Nondiscrimination Protections For People With Disabilities

MedCity News

HHS released a new proposed rule to update nearly 50-year old regulations protecting people with disabilities from discrimination while seeking healthcare. With its new proposal, HHS is amending the regulations to be clearer in their language, as well as more aligned with the Americans with Disabilities Act, the Americans with Disabilities Amendments Act and amendments to the Rehabilitation Act.

article thumbnail

Gain new perspectives on global research: Unveiling the dynamic G20 scorecard from ISI

Clarivate

We are proud to introduce fresh insights into measuring global research performance via our dynamic G20 scorecard for 2023, newly enhanced with online data visualizations. This guide to understanding the G20 scorecard explores how this interactive tool expands our perspective of global research and innovation. Each year, prior to the G20 Summit of the heads of state of the member nations, the Institute for Scientific Information (ISI) at Clarivate releases its annual G20 scorecard.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Marketing to Baby Boomers: 9 Key Insights Especially Relevant to Healthcare

Healthcare Success

Today, the marketing spotlight often shines on Millennials, Gen Z, and Gen X due to their vast numbers, combined influence, and economic power. However, marketing to Baby Boomers remains vitally important. At approximately 68.6 million strong, Baby Boomers remain a formidable and highly-valuable consumer segment. Unfortunately, when building their marketing strategies, many marketers fail to truly understand Baby Boomers, including their rich and nuanced history, disposable income, diversity, an

Marketing 113
article thumbnail

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts

Fierce Pharma

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma 333

More Trending

article thumbnail

Improving Health Equity and Diversity Throughout the Life Sciences

PM360

Since 2020, diversity, equity, and inclusion (DE&I) has been a prime area of attention within healthcare and the life sciences. For one, the pandemic put a spotlight on the disparity within clinical trials—in 2020 the FDA found that 75% of trial participants were white, 11% were Hispanic, 8% were Black, and 6% were Asian. Furthermore, the rise of the Black Lives Matter movement at the time forced organizations in all industries to take a closer look at their DE&I efforts and inspired som

article thumbnail

Neuroplast spinal cord injury study milestone

PharmaTimes

The trial analyses the impact of its ‘Neuro-Cells’ among patients with traumatic spinal cord injuries - News - PharmaTimes

Patients 124
article thumbnail

J&J's patient assistance program suffers data breach, IBM says

Fierce Pharma

IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.

Patients 335
article thumbnail

Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology

MedCity News

By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.

Biopharma 127
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Will AI Completely Transform the Patient Experience?

PM360

The healthcare system might not be too keen to hang this report card on the fridge: 26% of Americans rated their healthcare experience as a D (18%) or an F (8%), while 34% gave it a solid C and only 10% gave it an A, that’s according the American Academy of Physician Associates (AAPA) and The Harris Poll’s survey of 2,519 adults age 18+ conducted between February 23 and March 9, 2023. 1 For 65% of respondents, one of the biggest issues was that coordinating and managing healthcare is overwhelmin

Patients 111
article thumbnail

CRISPR-Equipped Bacteria Detect Tumors

Medgadget

Researchers at the University of California San Diego have created a bacterial sentinel system that can alert clinicians to the presence of tumors. The technology takes advantage of the specificity of the CRISPR system and the tendency of bacteria to uptake fragments of DNA from their environment. Termed “Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer” (CATCH), the system has been created to detect gastrointestinal tumors in its first iteration.

article thumbnail

Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list

Fierce Pharma

Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act (IRA). | Add Novartis to the list of biopharma giants that have filed lawsuits against the U.S. government as a reaction to the Inflation Reduction Act. The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 296
article thumbnail

Alignment Health: What Are Seniors’ Top Barriers to Care?

MedCity News

A new survey from Alignment Health found that economic instability, food insecurity, lack of support and transportation access are the biggest social barriers for seniors.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Unconventional Approaches Pharma Is Taking to Engage Patients

PM360

The “Kama Sutra” for Parkinson’s patients. A card game designed to help hemophilia patients exercise. A virtual product launch for patients akin to an iPhone debut. Documentaries, children’s books, Marvel comics, and interactive zines. All of these are examples of how companies are taking a little more unconventional approach to patient engagement. “The notion of radical empathy is something that has guided us when engaging patients,” says Ryan Mason, Chief Marketing and Creative Officer, Fishaw

Patients 105
article thumbnail

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Pharmaceutical Technology

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Biopharma 119
article thumbnail

Astellas withdraws IRA lawsuit after avoiding CMS' price negotiations list

Fierce Pharma

Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act (IRA). | Expecting to be subject to Medicare pricing negotiations, Astellas in July challenged the legality of the Inflation Reduction Act. But now that the Centers for Medicare & Medicaid Services has released the first 10 drugs set for governmental bargaining, the company is ready to abandon its litigation.

291
291
article thumbnail

MA Beneficiaries With Cancer Spend Less on Healthcare Than Traditional Medicare Beneficiaries

MedCity News

Medicare Advantage beneficiaries with a cancer diagnosis spend $3,996 on out-of-pocket costs and premiums annually, versus $6,091 for traditional Medicare beneficiaries with cancer, a new report found.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Two Key Questions About Patient Experience in 2023

PM360

PM360 asked experts in delivering optimal patient experiences how the industry can better understand what patients need and what is likely to be the biggest change to how patients experience healthcare in the coming years. Specifically, we wanted to know: How can life sciences companies and marketers develop fuller, more complete pictures of patients to better serve their needs and deliver better experiences?

Patients 105
article thumbnail

NICE recommends new type 2 diabetes treatment

European Pharmaceutical Review

Eli Lilly ’s Mounjaro (tirzepatide), has been recommended to treat poorly controlled type 2 diabetes in adults alongside diet and exercise. National Institute for Health and Care Excellence (NICE) final draft guidance recommends tirzepatide as a new treatment option for this indication. Compared with semaglutide , insulin therapy or a placebo, tirzepatide demonstrated that 81 percent to 97 percent of people achieved better glucose control in clinical trials.

article thumbnail

BlueWhale Bio surfaces with $18M on mission to overhaul cell therapy production

Fierce Pharma

University of Pennsylvania spinout BlueWhale Bio has surfaced on a mission to smash bottlenecks in cell and gene therapy manufacturing. | Cell therapy manufacturer BlueWhale Bio uncloaked Thursday with news it has raised $18 million in seed financing. The funding round was led by Danaher Corporation.

article thumbnail

5 Foundational Capabilities Needed for Implementing a Value-Based Care Program

MedCity News

Apprehension among practices and providers is understandable, given the complexity and variance of VBC contracts. However, instead of feeling overwhelmed and burdened by VBC, practices can slowly embrace these concepts by leveraging the many tools they already have in place or that exist in the healthcare ecosystem.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Strategies for Success in an Evolving Commercialization Landscape

PharmExec

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

article thumbnail

Alzheimer’s senescent cell combination therapy presents promise

European Pharmaceutical Review

A Phase I trial employing the drug dasatinib has shown promise in clearing senescent cells in Alzheimer’s. Recent drugs targeting beta-amyloid plaques have only yielded modest results, according to the study researchers. Instead, the current US study pursued cellular senescence as an alternative area of focus. The findings published in Nature Medicine described how the US Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor dasatinib was used in combination with quercetin, a pla

article thumbnail

J&J dumps high-dose Opsumit trial upon failure in rare type of pulmonary hypertension

Fierce Pharma

Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag. | J&J’s Janssen has decided to stop a phase 3 trial for a high dose of Opsumit in a subtype of pulmonary hypertension. With the flop, J&J loses a chance to challenge Bayer's Adempas.

278
278
article thumbnail

Mercer: Cost of Health Benefits To Jump 5.4% in 2024

MedCity News

Employers expect health benefit costs to increase 5.4% per employee on average in 2024, new data from Mercer shows. This is due to inflationary pressures and health system consolidation.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

The Stories That Shine

PharmExec

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work.

article thumbnail

Hope sputters for emerging anti-TIGIT drug class

PharmaVoice

Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

Patients 105
article thumbnail

Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes

Fierce Pharma

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. | Roche may not receive the FDA's decision on a subcutaneous version of its cancer immunotherapy Tecentriq on time thanks to the agency's requirement for changes to the drug's manufacturing process.

article thumbnail

A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy

MedCity News

Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.

Biopharma 117
article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.